TickerFacts.

Company research / FATE

Fate Therapeutics Inc (FATE)

Build a valuation ↗↓ Download CSV

SEC name FATE THERAPEUTICS INC · CIK 0001434316 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Fate Therapeutics Inc reported revenue of $6.65M. Revenue fell 51.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $6.49M.

Key ratios (year ended 2025-12-31)

n/m
Operating margin
n/m
Net margin
-65.8%
Return on year-end equity
-51.2%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-28

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$6.49M$6.65M$13.63M$63.53M$96.30M$55.85M$31.43M$10.68M$4.74M$4.11M$4.40M
R&D Expense$100.35M$107.83M$135.00M$172.60M$320.45M$215.52M$125.62M$87.77M$56.02M$34.36M$26.45M
Operating Income-$133.59M-$147.70M-$210.28M-$190.51M-$308.39M-$216.99M-$128.09M-$100.73M-$67.09M-$42.12M-$31.96M
Depreciation & Amortization$11.99M$12.90M$18.96M$18.28M$13.76M$5.85M$3.09M$2.19M$1.20M$971.0K$881.0K
EBITDA-$121.60M-$134.80M-$191.31M-$172.23M-$294.63M-$211.14M-$125.00M-$98.53M-$65.89M-$41.15M-$31.08M
Net Income-$126.00M-$136.31M-$186.26M-$160.93M-$281.72M-$212.15M-$173.39M-$98.15M-$66.60M-$42.95M-$33.46M
EPS (Diluted)n/a-$1.15-$1.64-$1.64-$2.91-$2.24-$2.10n/an/an/an/a
Total Assets$260.10M$318.94M$440.69M$506.22M$705.56M$921.46M$622.46M$302.27M$213.03M$105.29M$95.05M
Long-Term Debtn/an/an/an/an/an/an/an/a$18.48M$19.32M$12.81M
Shareholders' Equity$153.44M$207.18M$318.73M$368.42M$483.94M$678.84M$384.44M$244.76M$160.47M$77.19M$73.15M
Cash & Equivalents$32.43M$46.63M$36.06M$41.87M$61.33M$133.58M$167.35M$99.81M$190.51M$88.95M$88.61M
Operating Cash Flow-$101.94M-$106.08M-$122.87M-$132.26M-$248.21M-$162.87M-$39.23M-$83.17M-$38.65M-$36.82M-$29.82M
Capital Expenditures$3.71M$5.95M$730.0K$6.15M$35.57M$50.70M$4.93M$7.39M$2.30M$1.73M$457.0K
Free Cash Flow-$105.66M-$112.04M-$123.60M-$138.42M-$283.77M-$213.57M-$44.16M-$90.57M-$40.95M-$38.54M-$30.28M
Shares Outstanding116.69M115.36M113.93M98.63M97.29M95.73M87.72M75.73M64.69M52.65M41.39M
Weighted Average Diluted Sharesn/a118.79M113.69M98.41M96.83M94.75M82.39Mn/an/an/an/a
EPS (Basic)n/a-$1.15-$1.64-$1.64-$2.91-$2.24-$2.10n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView